Tethys said that the patent was issued following an accelerated review procedure which enables innovators to receive a final decision within 12 months of application.

PreDx DRS is a simple-to-use, multimarker blood test that enables accurate identification of patients who have the highest risk of developing type 2 diabetes within five years.

Tethys Bioscience claimed that PreDx DRS facilitates identification of the 10-20% of individuals at the highest, near-term risk of diabetes. PreDx DRS offers an accurate, validated tool to identify patients at imminent risk of developing chronic cardiometabolic disease before disease progression.

Mickey Urdea, chairman and COO of Tethys, said: “The rapid issuance of this first PreDx patent reflects the company’s commitment to an intellectual property portfolio that will support its rapid commercialization of novel technology to identify patients at risk of developing type 2 diabetes and other chronic cardiometabolic diseases.

“The cost of treating all patients at risk for diabetes is not sustainable and threatens to break the US healthcare system. We believe that the direct impact of PreDx DRS will be to mitigate the type 2 diabetes epidemic and lower healthcare costs by providing physicians with a powerful tool that will enable them to focus preemptive interventions on patients most at risk of developing the disease.”